Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) prognosis has significantly improved with tyrosine kinase inhibitor (TKI) therapy, leading to life expectancies comparable to the general population.
• Monitoring treatment success via quantitative polymerase chain reaction (PCR) and assessing patient-reported outcomes (PROs) are crucial for managing CML.
• Managing adverse events associated with TKIs is essential for improving patient compliance and quality of life.

Purpose of the Study:

• To review the current landscape of chronic phase CML management.
• To highlight the importance of monitoring treatment response and managing adverse events.
• To explore the emerging strategy of TKI discontinuation in CML.

Main Methods:

• Review of current literature and clinical guidelines on CML management.
• Discussion of monitoring techniques including quantitative PCR and PROs.
• Analysis of data regarding TKI discontinuation and treatment-free remission.

Main Results:

• TKI therapy has normalized life expectancy for CML patients with good response.
• Quantitative PCR and PROs are reliable tools for assessing TKI efficacy and tolerance.
• Approximately 50% of selected CML patients can achieve durable treatment-free remission after TKI discontinuation.
• Provider multi-team coaching enhances patient engagement in TKI discontinuation, improving safety.

Conclusions:

• Effective management of CML involves monitoring treatment response, managing adverse events, and considering comorbidities.
• TKI discontinuation is a viable and promising strategy for select CML patients.
• Patient-centered approaches, including multi-team coaching, are vital for successful and safe TKI discontinuation in CML management.